Injectable Drug SB-6 Recalled for Manufacturing Quality Control Deviations
Olympia Compounding Pharmacy recalls SB-6 injectable drug due to manufacturing deficiencies. Prior to October 2021, environmental and personnel monitoring procedures were not properly investigated.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II drug recall without reported hospitalizations or injuries. The deficiency involves inadequate manufacturing quality control monitoring. The recall of a pharmaceutical injectable product due to manufacturing quality control deviations constitutes a risk-of-harm situation where injury has not yet been reported.
Plain-English summary
Olympia Compounding Pharmacy dba Olympia Pharmacy is recalling SB-6, a multi-dose injectable pharmaceutical product containing Papaverine 30 mg/mL, Phentolamine 3 mg/mL, and PGE 60 mcg/mL. A total of 336 vials with lot numbers E41H18 (BUD 5/18/2022) and G41319 (BUD 7/19/2022) are affected. The product was distributed nationwide in the USA.
The recall was initiated due to manufacturing deficiencies related to Current Good Manufacturing Practice (CGMP) compliance. Prior to October 1, 2021, the facility did not properly investigate Out of Action Limit (OOAL) excursions in environmental and personnel monitoring protocols. This represents a quality control deviation in the manufacturing process.
Patients currently using this product should consult their healthcare provider or pharmacist immediately regarding their treatment. Do not discontinue use without medical guidance. Healthcare providers should check their inventory for the affected lot numbers and contact affected patients.
The recalled product
- Product
- SB-6, Papaverine 30 mg/mL . Phentolamine 3 mg/mL . PGE 60 mcg/mL, Multi-Dose 10 mL vial, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0025-10.
- Category
- Drug — Compounded Injectable
- Affected units
- 336
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: E41H18 BUD: 5/18/2022
- G41319 BUD: 7/19/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 34 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 34 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
- HighCompounded Injectable Formula F1 Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19